https://www.selleckchem.com/pr....oducts/nedisertib.ht
was the leading ESBL-producing followed by and with a prevalence of 74, 67 and 60 %, respectively. ESBL-producing isolates showed a high rate of resistance to cefotaxime, ceftriaxone, ceftazidime, Amoxicillin clavulanic acid (AMC), ampicillin and aztreonam. The better options for the treatment of ESBL-producing are amikacin and Imipenem. The magnitude of ESBL-producing in different clinical samples in Ethiopia is alarmingly high and represents a threat to human health. Hence, a coordinated effort needs to be implemented for the preve
Like
Comment
Share
